Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 142,180 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Gilead Sciences Price Performance

GILD stock opened at $98.38 on Tuesday. The firm has a 50-day moving average of $92.42 and a two-hundred day moving average of $85.96. The firm has a market capitalization of $122.61 billion, a PE ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. BMO Capital Markets boosted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Mizuho boosted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Monday. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth approximately $25,000. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Finally, Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.